欧洲子宫腺肌病药物市场 - 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

欧洲子宫腺肌病药物市场 - 行业趋势和 2029 年预测

  • Pharmaceutical
  • Published Report
  • May 2022
  • Europe
  • 350 页面
  • 桌子數: 587
  • 图号: 45

>欧洲子宫腺肌病药物市场,按类型(弥漫性、结节性、硬化性、成人囊性和其他)、治疗(激素药物、抗炎药物和其他)、患者类型(成人、老年和青少年)、剂型(肠胃外、口服、其他)、最终用户(医院、诊所、专科中心、家庭医疗保健、门诊中心和其他)、分销渠道(医院药房、零售药房、网上药房和其他)划分 - 行业趋势和预测到 2029 年。

欧洲子宫腺肌病药物市场

市场分析和见解

子宫腺肌病是一种良性子宫疾病,病理上表现为子宫内膜腺体和基质位于子宫肌层内。患有子宫腺肌病的女性可能出现异常子宫出血 (AUB)、痛经、性交困难或不孕,但其中三分之一没有症状。多年来,子宫腺肌病一直是围绝经期女性在子宫切除术后出现的月经过多 (HMB) 或盆腔痛的组织病理学诊断。然而,由于近年来成像技术的进步,子宫腺肌病在过去十年中也成为年轻育龄女性中发现的一种疾病,尽管仍然缺乏共同的定义和分类。尽管诊断工具有所改进,但对该疾病的认识仍然很差。

子宫腺肌病药物市场

子宫腺肌病药物市场

治疗子宫腺肌病的药物一般包括抗炎药和激素类药物,例如促性腺激素释放激素类似物(Gnrh Analogs)、雌孕激素、选择性孕激素受体调节剂(SPRMs)或孕激素、芳香化酶抑制剂、促性腺激素释放激素拮抗剂等,部分药物用于缩小子宫腺肌病灶,改善患者的痛经和生活质量。

发达国家对子宫腺肌病药物的需求有所增加。这些国家有治疗报销政策,疾病患病率高,医疗费用不断增加。由于新兴市场的探索以及私人和政府机构对治疗的支持不断增加,预测期内市场将增长。 

欧洲子宫腺肌病药物市场报告提供了市场份额、新发展、国内和本地化市场参与者的影响的详细信息,分析了新兴收入来源、市场变化等方面的机会

rket regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. Strategic initiatives such as collaboration, agreement, and signing of sales agreements to invent and innovate pharmacological treatments are the major drivers which propelled the demand of the market in the forecast period.

Europe adenomyosis drugs market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the Europe adenomyosis drugs market will grow at a CAGR of 5.6% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Thousand, Pricing in USD

Segments Covered

By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others),  Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others),  Patient Type (Adult, Geriatric, and Adolescence ), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)

Countries Covered

Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe

Market Players Covered

Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.

Market Definition

Adenomyosis represents a unique pathophysiological condition in which normal-appearing endometrial mucosa resides within the myometrium and is thus protected from menstrual shedding. The resulting ectopic presence of endometrial tissue composed of glands and stroma is thought to affect normal contractile function and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and adverse obstetric outcomes. Adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work productivity without mentioning the compromised quality of life.

Adenomyosis has a negative impact on women's quality of life in a high percentage of cases because of abnormal uterine bleeding and pain requiring a lifelong management plan through medical or surgical treatment. The choice depends on the woman's age, reproductive status, and clinical symptoms. However, the disease is increasingly diagnosed in young women with reproductive desire, and conservative treatments are preferred, such as hormonal medications.

Europe Adenomyosis Drugs Market Dynamics

Drivers

  • High prevalence of adenomyosis disorders

Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, endometriosis, adenomyosis, abnormal vaginal bleeding, and breast pain and lumps, among others. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.

With the increasing women population worldwide, the target population for female reproductive disorder has also increased. Adenomyosis, a gynecologic condition characterized by the presence of endometrial glands and stroma within the myometrium, can significantly reduce the lifestyle of an individual. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women.

  • Advancement in the diagnosis of adenomyosis

The development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women also undergoing conservative treatments, identifying different phenotypes of the disease. After some attempts of histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium: intrinsic, extrinsic, intramural, and indeterminate. 

Opportunity

  • Increase demand for disease-specific drug treatment

According to pathogenic mechanisms, several medical hormonal and non-hormonal treatments are used off-label to manage pain and bleeding and to improve fertility outcomes. The use of GnRHa is indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis, and the highest pregnancy rate is reported in those undergoing frozen embryo transfer after GnRHa pre-treatment. In contrast, the use of GnRHa for pain and bleeding should be considered only for short-term treatment because of menopausal effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) is also an effective, reversible, and long-term treatment used successfully to treat adenomyosis. Results show that it reduces menstrual bleeding, pain, and uterine volume and has an overall satisfaction of 72%. However, new drugs, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelet therapy, are under development for the treatment of adenomyosis.

Restraints/Challenges

The diagnostic tests for adenomyosis include highly technologically advanced products. The development of those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing. The diagnostic tools and techniques used for the diagnosis of adenomyosis include ovarian endometrioma, adhesions, and deep nodular forms of the disease that often require ultrasonography or magnetic resonance imaging (MRI) to detect. Histologic verification, usually following surgical/laparoscopic visualization, can be useful in confirming the diagnosis, particularly for the most common superficial lesions.

The therapy of adenomyosis involves different stages and different procedures of treatment. Adenomyosis may be treated with surgery, hormonal drugs, anti-inflammatory drugs, etc. The diagnosis of adenomyosis is difficult, and this subsequently results in difficulty in the management of these patients, especially those who are asymptomatic but have a strong desire to preserve their uterus. Herbal drugs and home remedies are used as alternative therapies for the treatment of adenomyosis.

Recent Developments

  • In October 2021, Debiopharm, a Swiss-based, Asia-Pacific biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly adenomyosis, and its related diseases
  • In September 2019, Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 Million (AUD 3.05 Million) grant to determine the cause of adenomyosis and the physiological processes associated with the diseases

Europe Adenomyosis Drugs Market Divide

欧洲子宫腺肌病药物市场根据类型、治疗、患者类型、剂型、分销渠道和最终用户分为六个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

类型

  • 扩散
  • 结节性
  • 硬化
  • 成人囊性
  • 其他的

根据类型,欧洲子宫腺肌病药物市场分为弥漫型、结节型、硬化型、成人囊性型和其他型。

治疗

  • 激素药物
  • 抗炎药物
  • 其他的

根据治疗方法,欧洲子宫腺肌病药物市场分为激素药物、抗炎药物和其他药物。

患者类型

  • 青春期
  • 成人
  • 老年

根据患者类型,欧洲子宫腺肌病药物市场分为青少年、成人和老年人。

剂型

  • 肠外
  • 口服
  • 其他的

根据剂型,欧洲子宫腺肌病药物市场分为肠外给药、口服和其他剂型。

最终用户

  • 医院
  • 诊所
  • 专业中心
  • 家庭医疗保健
  • 门诊中心
  • 其他的

根据最终用户,欧洲子宫腺肌病药物市场分为医院、诊所、专科中心、家庭医疗保健、门诊中心和其他。 

分销渠道

  • 医院药房 
  • 零售药店
  • 网上药店
  • 其他的

子宫腺肌病药物市场

根据分销渠道,欧洲子宫腺肌病药物市场分为医院药房、零售药房、网上药房和其他。

欧洲子宫腺肌病药物市场区域分析/见解

对欧洲子宫腺肌病药物市场进行了分析,并按类型、治疗、患者类型、剂型、分销渠道和最终用户提供了市场规模洞察和趋势,如上所述。

欧洲子宫腺肌病药物市场报告涵盖的国家包括德国、法国、意大利、英国、西班牙、俄罗斯、奥地利、荷兰、匈牙利、波兰、瑞士、土耳其、挪威、立陶宛、爱尔兰和欧洲其他地区。

由于德国医疗保健支出不断增加,预计预测期内德国将占据市场主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。   

竞争格局和欧洲子宫腺肌病药物市场份额分析

欧洲子宫腺肌病药物市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对欧洲子宫腺肌病药物市场的关注有关。

市场的一些主要参与者包括 Mayne Pharma Group Limited、Accord Healthcare、Boehringer Ingelheim International GmbH、Ferring BV、Par Pharmaceutical(Endo International plc 的子公司)、Hikma Pharmaceuticals PLC、Viatris Inc.、Bayer AG、Teva Pharmaceutical Industries Ltd.、AstraZeneca、Pfizer Inc.、Sun Pharmaceutical Industries Ltd、AbbVie Inc.、Abbott、GlaxoSmithKline plc.、Novartis AG、Amneal Pharmaceuticals LLC、Johnson & Johnson Services, Inc.、Sanofi、Dr. Reddy's Laboratories Ltd. 等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、欧洲与地区以及供应商份额分析。如有进一步询问,请要求分析师致电。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE ADENOMYOSIS DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL'S MODEL

4.2 PORTER

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS FOR ADENOMYOSIS DRUGS MARKET

7 EUROPE ADENOMYOSIS DRUGS MARKET: REGULATORY SCENARIO

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 HIGH PREVALENCE OF ADENOMYOSIS DISORDERS

8.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG

8.1.3 ADVANCEMENT IN DIAGNOSIS OF ADENOMYOSIS

8.1.4 INCREASING AWARENESS OF ADENOMYOSIS

8.2 RESTRAINTS

8.2.1 HIGH COST OF TESTING AND MEDICATIONS

8.2.2 ADVERSE SIDE-EFFECTS OF ADENOMYOSIS DRUGS

8.3 OPPORTUNITIES

8.3.1 INCREASE DEMAND FOR DISEASE-SPECIFIC DRUG TREATMENT

8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS

8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT

8.4 CHALLENGES

8.4.1 ALTERNATIVE ADENOMYOSIS THERAPIES

8.4.2 IMPROPER DIAGNOSIS OF ADENOMYOSIS

9 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE

9.1 OVERVIEW

9.2 DIFFUSE

9.2.1 BY SYMPTOMS

9.2.1.1 MENORRHAGIA

9.2.1.2 PELVIC PAIN

9.2.1.3 DYSMENORRHEA

9.2.1.4 METRORRHAGIA

9.2.1.5 OTHERS

9.2.2 BY AGE

9.2.2.1 BETWEEN 20 TO 45

9.2.2.2 ABOVE 45

9.2.2.3 BEFORE 20

9.3 NODULAR

9.3.1 BY SYMPTOMS

9.3.1.1 MENORRHAGIA

9.3.1.2 PELVIC PAIN

9.3.1.3 DYSMENORRHEA

9.3.1.4 METRORRHAGIA

9.3.1.5 OTHERS

9.3.2 BY AGE

9.3.2.1 BETWEEN 20 TO 45

9.3.2.2 ABOVE 45

9.3.2.3 BEFORE 20

9.4 SCLEROTIC

9.4.1 BY SYMPTOMS

9.4.1.1 MENORRHAGIA

9.4.1.2 PELVIC PAIN

9.4.1.3 DYSMENORRHEA

9.4.1.4 METRORRHAGIA

9.4.1.5 OTHERS

9.4.2 BY AGE

9.4.2.1 BETWEEN 20 TO 45

9.4.2.2 ABOVE 45

9.4.2.3 BEFORE 20

9.5 ADULT CYSTIC

9.5.1 BY SYMPTOMS

9.5.1.1 MENORRHAGIA

9.5.1.2 PELVIC PAIN

9.5.1.3 DYSMENORRHEA

9.5.1.4 METRORRHAGIA

9.5.1.5 OTHERS

9.5.2 BY AGE

9.5.2.1 BETWEEN 20 TO 45

9.5.2.2 ABOVE 45

9.5.2.3 BEFORE 20

9.6 OTHERS

9.6.1 ATYPICAL POLYPOID ADENOMYOMAS

9.6.1.1 BY SYMPTOMS

9.6.1.1.1 MENORRHAGIA

9.6.1.1.2 PELVIC PAIN

9.6.1.1.3 DYSMENORRHEA

9.6.1.1.4 METRORRHAGIA

9.6.1.1.5 OTHERS

9.6.1.2 BY AGE

9.6.1.2.1 BETWEEN 20 TO 45

9.6.1.2.2 ABOVE 45

9.6.1.2.3 BEFORE 20

9.6.2 JUVENILE CYSTIC ADENOMYOSIS

9.6.2.1 BY SYMPTOMS

9.6.2.1.1 MENORRHAGIA

9.6.2.1.2 PELVIC PAIN

9.6.2.1.3 DYSMENORRHEA

9.6.2.1.4 METRORRHAGIA

9.6.2.1.5 OTHERS

9.6.2.2 BY AGE

9.6.2.2.1 BETWEEN 20 TO 45

9.6.2.2.2 ABOVE 45

9.6.2.2.3 BEFORE 20

10 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 HORMONE MEDICATIONS

10.2.1 GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS)

10.2.1.1 LEUPROLIDE ACETATE

10.2.1.2 NAFARELIN

10.2.1.3 GOSERELIN

10.2.1.4 OTHERS

10.2.2 ESTROGEN-PROGESTIN

10.2.2.1 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)

10.2.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)

10.2.2.3 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P)

10.2.2.4 OTHERS

10.2.3 SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN

10.2.3.1 LEVONORGESTREL

10.2.3.2 MIFEPRISTONE

10.2.3.3 ASOPRISNIL

10.2.3.4 LONAPRISAN

10.2.3.5 TELAPRISTONE ACETATE

10.2.3.6 ULIPRISTAL ACETATE

10.2.3.7 ONAPRISTONE

10.2.4 AROMATASE INHIBITORS

10.2.4.1 ARIMIDEX

10.2.4.2 FEMARA

10.2.4.3 OTHERS

10.2.5 GONADOTROPIN-RELEASING HORMONE ANTAGONIST

10.2.5.1 ELAGOLIX

10.2.5.2 FIRMAGON

10.2.5.3 OTHERS

10.2.6 SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)

10.2.6.1 TAMOXIFEN

10.2.6.2 RALOXIFENE

10.2.6.3 BAZEDOXIFENE

10.2.6.4 CLOMIPHENE

10.2.6.5 TOREMIFENE

10.2.6.6 OSPEMIFENE

10.2.6.7 LASOFOXIFENE

10.2.7 ANDROGEN DERIVATIVES

10.2.7.1 DANAZOL

10.2.7.2 GESTRINONE

10.3 ANTI-INFLAMMATORY DRUGS

10.3.1 NON-SELECTIVE NSAIDS

10.3.1.1 IBUPROFEN

10.3.1.2 NAPROXEN

10.3.1.3 DICLOFENAC

10.3.1.4 MEFENAMIC ACID

10.3.1.5 PIROXICAM

10.3.1.6 OTHERS

10.3.2 SELECTIVE COX-2 NSAIDS

10.3.2.1 CELECOXIB

10.3.2.2 VALDECOXIB

10.3.2.3 OTHERS

10.3.3 PREFERENTIAL COX-2 INHIBITORS

10.3.3.1 MELOXICAM

10.3.3.2 ETODOLAC

10.3.3.3 OTHERS

10.4 OTHERS

11 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE

11.1 OVERVIEW

11.2 ADULT

11.3 GERIATRIC

11.4 ADOLESCENCE

12 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM

12.1 OVERVIEW

12.2 ORAL

12.2.1 TABLETS

12.2.2 CAPSULES

12.2.3 SOLUTION

12.2.4 SUSPENSION

12.3 PARENTERAL

12.3.1 INTRAVENOUS

12.3.2 INTRAMUSCULAR

12.4 OTHERS

13 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 SPECIALTY CENTER

13.5 HOME HEALTHCARE

13.6 AMBULATORY CENTERS

13.7 OTHERS

14 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 ONLINE PHARMACY

14.5 OTHERS

15 EUROPE ADENOMYOSIS DRUGS MARKET, BY REGION

15.1 EUROPE

15.1.1 GERMANY

15.1.2 U.K.

15.1.3 FRANCE

15.1.4 ITALY

15.1.5 SPAIN

15.1.6 RUSSIA

15.1.7 NETHERLANDS

15.1.8 SWITZERLAND

15.1.9 POLAND

15.1.10 TURKEY

15.1.11 HUNGARY

15.1.12 AUSTRIA

15.1.13 NORWAY

15.1.14 IRELAND

15.1.15 LITHUANIA

15.1.16 REST OF EUROPE

16 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 ABBVIE INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.1.5.1 ACQUISITION

18.1.5.2 PARTNERSHIP

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.2.5.1 MERGER

18.3 SANOFI

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.3.5.1 MERGER

18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.4.5.1 PARTNERSHIP

18.5 BAYER AG

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.5.5.1 ACQUISITION

18.6 ABBOTT

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.6.4.1 PRODUCT APPROVAL

18.7 ACCORD HEALTHCARE

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENT

18.8 AMNEAL PHARMACEUTICALS LLC

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENTS

18.8.4.1 EVENT

18.9 ASTRAZENECA

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.9.4.1 EXPANSION

18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENT

18.11 CONTEXT THERAPEUTICS INC.

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.11.3.1 EVENT

18.12 DR. REDDY’S LABORATORIES LTD.

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENT

18.12.4.1 ACQUISITION

18.13 FERRING B.V.

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENTS

18.13.3.1 COLLABORATION

18.14 GLAXOSMITHKLINE PLC

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENTS

18.14.4.1 PARTNERSHIP

18.15 HIKMA PHARMACEUTICALS PLC

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 JOHNSON & JOHNSON SERVICES, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENT

18.16.4.1 EVENT

18.17 LANNETT

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.17.4.1 EVENT

18.18 MAYNE PHARMA GROUP LIMITED

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENT

18.18.4.1 PRODUCT LAUNCH

18.19 NOVARTIS AG

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 PRODUCT PORTFOLIO

18.19.4 RECENT DEVELOPMENTS

18.19.4.1 PRODUCT DEVELOPMENT

18.19.4.2 ACQUISITION

18.2 PAR PHARMACEUTICAL ( A SUBSIDIARY OF ENDO INTERNATIONAL PLC)

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENTS

18.21 SUN PHARMACEUTICAL INDUSTRIES LTD

18.21.1 COMPANY SNAPSHOT

18.21.2 REVENUE ANALYSIS

18.21.3 PRODUCT PORTFOLIO

18.21.4 RECENT DEVELOPMENT

18.22 TERSERA THERAPEUTICS LLC

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENT

18.22.3.1 AGREEMENT

18.23 TOLMAR PHARMACEUTICALS, INC.

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENT

18.23.3.1 PRODUCT LAUNCH

18.23.3.2 EXPANSION

18.24 VIATRIS INC

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

18.24.4.1 AGREEMENT

18.25 ZYDUS PHARMACEUTICALS, INC.

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENTS

18.25.3.1 ACQUISITION

19 QUESTIONNAIRE

20 RELATED REPORTS

表格列表

TABLE 1 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 2 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 3 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 4 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 5 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 7 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 8 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 9 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 10 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 11 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 12 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 13 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 14 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 15 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 16 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 17 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 18 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 19 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 20 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 21 EUROPE HORMONE MEDICATION IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 22 EUROPE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 23 EUROPE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 24 EUROPE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 25 EUROPE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 26 EUROPE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 27 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 28 EUROPE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 29 EUROPE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 30 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 32 EUROPE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 33 EUROPE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 34 EUROPE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 35 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 36 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 37 EUROPE ADULT IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 38 EUROPE GERIATRIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39 EUROPE ADOLESCENCE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 41 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 43 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 45 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 46 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 47 EUROPE HOSPITAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48 EUROPE CLINICS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 49 EUROPE SPECIALTY CENTER IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50 EUROPE HOME HEALTHCARE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 51 EUROPE AMBULATORY CENTERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 52 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 53 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 54 EUROPE HOSPITAL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 55 EUROPE RETAIL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 56 EUROPE ONLINE PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 57 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 58 EUROPE ADENOMYOSIS DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 59 EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 60 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 61 EUROPE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 62 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 63 EUROPE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 64 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 65 EUROPE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 66 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 67 EUROPE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 68 EUROPE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 69 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 70 EUROPE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 71 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 72 EUROPE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 73 EUROPE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 74 EUROPE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 75 EUROPE GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 76 EUROPE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 77 EUROPE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 78 EUROPE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 79 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 80 EUROPE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 81 EUROPE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 82 EUROPE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 83 EUROPE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 84 EUROPE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 85 EUROPE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 86 EUROPE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 87 EUROPE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 88 EUROPE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 89 EUROPE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 90 EUROPE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 91 EUROPE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 92 GERMANY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 93 GERMANY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 94 GERMANY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 95 GERMANY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 96 GERMANY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 97 GERMANY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 98 GERMANY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 99 GERMANY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 100 GERMANY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 101 GERMANY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 102 GERMANY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 103 GERMANY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 104 GERMANY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 105 GERMANY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 106 GERMANY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 107 GERMANY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 108 GERMANY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 109 GERMANY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 110 GERMANY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 111 GERMANY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 112 GERMANY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 113 GERMANY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 114 GERMANY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 115 GERMANY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 116 GERMANY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 117 GERMANY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 118 GERMANY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 119 GERMANY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 120 GERMANY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 121 GERMANY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 122 GERMANY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 123 GERMANY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 124 GERMANY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 125 U.K. ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 126 U.K. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 127 U.K. DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 128 U.K. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 129 U.K. NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 130 U.K. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 131 U.K. SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 132 U.K. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 133 U.K. ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 134 U.K. OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 135 U.K. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 136 U.K. ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 137 U.K. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 138 U.K. JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 139 U.K. ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 140 U.K. HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 141 U.K. GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 142 U.K. ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 143 U.K. SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 144 U.K. AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 145 U.K. GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 146 U.K. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 147 U.K. ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 148 U.K. ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 149 U.K. NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 150 U.K. SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 151 U.K. PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 152 U.K. ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 153 U.K. ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 154 U.K. ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 155 U.K. PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 156 U.K. ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 157 U.K. ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 158 FRANCE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 159 FRANCE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 160 FRANCE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 161 FRANCE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 162 FRANCE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 163 FRANCE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 164 FRANCE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 165 FRANCE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 166 FRANCE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 167 FRANCE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 168 FRANCE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 169 FRANCE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 170 FRANCE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 171 FRANCE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 172 FRANCE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 173 FRANCE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 174 FRANCE GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 175 FRANCE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 176 FRANCE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 177 FRANCE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 178 FRANCE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 179 FRANCE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 180 FRANCE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 181 FRANCE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 182 FRANCE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 183 FRANCE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 184 FRANCE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 185 FRANCE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 186 FRANCE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 187 FRANCE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 188 FRANCE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 189 FRANCE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 190 FRANCE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 191 ITALY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 192 ITALY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 193 ITALY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 194 ITALY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 195 ITALY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 196 ITALY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 197 ITALY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 198 ITALY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 199 ITALY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 200 ITALY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 201 ITALY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 202 ITALY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 203 ITALY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 204 ITALY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 205 ITALY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 206 ITALY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 207 ITALY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 208 ITALY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 209 ITALY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 210 ITALY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 211 ITALY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 212 ITALY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 213 ITALY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 214 ITALY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 215 ITALY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 216 ITALY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 217 ITALY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 218 ITALY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 219 ITALY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 220 ITALY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 221 ITALY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 222 ITALY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 223 ITALY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 224 SPAIN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 225 SPAIN DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 226 SPAIN DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 227 SPAIN NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 228 SPAIN NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 229 SPAIN SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 230 SPAIN SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 231 SPAIN ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 232 SPAIN ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 233 SPAIN OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 234 SPAIN ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 235 SPAIN ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 236 SPAIN JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 237 SPAIN JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 238 SPAIN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 239 SPAIN HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 240 SPAIN GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 241 SPAIN ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 242 SPAIN SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 243 SPAIN AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 244 SPAIN GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 245 SPAIN SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 246 SPAIN ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 247 SPAIN ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 248 SPAIN NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 249 SPAIN SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 250 SPAIN PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 251 SPAIN ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 252 SPAIN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 253 SPAIN ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 254 SPAIN PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 255 SPAIN ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 256 SPAIN ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 257 RUSSIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 258 RUSSIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 259 RUSSIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 260 RUSSIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 261 RUSSIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 262 RUSSIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 263 RUSSIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 264 RUSSIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 265 RUSSIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 266 RUSSIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 267 RUSSIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 268 RUSSIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 269 RUSSIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 270 RUSSIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 271 RUSSIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 272 RUSSIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 273 RUSSIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 274 RUSSIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 275 RUSSIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 276 RUSSIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 277 RUSSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 278 RUSSIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 279 RUSSIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 280 RUSSIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 281 RUSSIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 282 RUSSIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 283 RUSSIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 284 RUSSIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 285 RUSSIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 286 RUSSIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 287 RUSSIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 288 RUSSIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 289 RUSSIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 290 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 291 NETHERLANDS DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 292 NETHERLANDS DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 293 NETHERLANDS NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 294 NETHERLANDS NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 295 NETHERLANDS SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 296 NETHERLANDS SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 297 NETHERLANDS ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 298 NETHERLANDS ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 299 NETHERLANDS OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 300 NETHERLANDS ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 301 NETHERLANDS ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 302 NETHERLANDS JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 303 NETHERLANDS JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 304 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 305 NETHERLANDS HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 306 NETHERLANDS GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 307 NETHERLANDS ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 308 NETHERLANDS SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 309 NETHERLANDS AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 310 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 311 NETHERLANDS SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 312 NETHERLANDS ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 313 NETHERLANDS ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 314 NETHERLANDS NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 315 NETHERLANDS SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 316 NETHERLANDS PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 317 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 318 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 319 NETHERLANDS ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 320 NETHERLANDS PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 321 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 322 NETHERLANDS ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 323 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 324 SWITZERLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 325 SWITZERLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 326 SWITZERLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 327 SWITZERLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 328 SWITZERLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 329 SWITZERLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 330 SWITZERLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 331 SWITZERLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 332 SWITZERLAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 333 SWITZERLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 334 SWITZERLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 335 SWITZERLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 336 SWITZERLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 337 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 338 SWITZERLAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 339 SWITZERLAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 340 SWITZERLAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 341 SWITZERLAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 342 SWITZERLAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 343 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 344 SWITZERLAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 345 SWITZERLAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 346 SWITZERLAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 347 SWITZERLAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 348 SWITZERLAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 349 SWITZERLAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 350 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 351 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 352 SWITZERLAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 353 SWITZERLAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 354 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 355 SWITZERLAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 356 POLAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 357 POLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 358 POLAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 359 POLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 360 POLAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 361 POLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 362 POLAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 363 POLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 364 POLAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 365 POLAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 366 POLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 367 POLAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 368 POLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 369 POLAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 370 POLAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 371 POLAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 372 POLAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 373 POLAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 374 POLAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 375 POLAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 376 POLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 377 POLAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 378 POLAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 379 POLAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 380 POLAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 381 POLAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 382 POLAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 383 POLAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 384 POLAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 385 POLAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 386 POLAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 387 POLAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 388 POLAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 389 TURKEY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 390 TURKEY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 391 TURKEY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 392 TURKEY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 393 TURKEY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 394 TURKEY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 395 TURKEY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 396 TURKEY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 397 TURKEY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 398 TURKEY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 399 TURKEY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 400 TURKEY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 401 TURKEY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 402 TURKEY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 403 TURKEY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 404 TURKEY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 405 TURKEY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 406 TURKEY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 407 TURKEY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 408 TURKEY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 409 TURKEY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 410 TURKEY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 411 TURKEY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 412 TURKEY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 413 TURKEY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 414 TURKEY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 415 TURKEY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 416 TURKEY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 417 TURKEY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 418 TURKEY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 419 TURKEY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 420 TURKEY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 421 TURKEY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 422 HUNGARY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 423 HUNGARY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 424 HUNGARY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 425 HUNGARY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 426 HUNGARY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 427 HUNGARY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 428 HUNGARY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 429 HUNGARY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 430 HUNGARY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 431 HUNGARY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 432 HUNGARY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 433 HUNGARY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 434 HUNGARY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 435 HUNGARY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 436 HUNGARY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 437 HUNGARY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 438 HUNGARY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 439 HUNGARY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 440 HUNGARY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 441 HUNGARY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 442 UNGARY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 443 HUNGARY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 444 HUNGARY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 445 HUNGARY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 446 HUNGARY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 447 HUNGARY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 448 HUNGARY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 449 HUNGARY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 450 HUNGARY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 451 HUNGARY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 452 HUNGARY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 453 HUNGARY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 454 HUNGARY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 455 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 456 AUSTRIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 457 AUSTRIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 458 AUSTRIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 459 AUSTRIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 460 AUSTRIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 461 AUSTRIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 462 AUSTRIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 463 AUSTRIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 464 AUSTRIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 465 AUSTRIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 466 AUSTRIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 467 AUSTRIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 468 AUSTRIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 469 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 470 AUSTRIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 471 AUSTRIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 472 AUSTRIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 473 AUSTRIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 474 AUSTRIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 475 AUSTRIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 476 AUSTRIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 477 AUSTRIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 478 AUSTRIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 479 AUSTRIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 480 AUSTRIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 481 AUSTRIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 482 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 483 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 484 AUSTRIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 485 AUSTRIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 486 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 487 AUSTRIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 488 NORWAY ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 489 NORWAY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 490 NORWAY DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 491 NORWAY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 492 NORWAY NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 493 NORWAY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 494 NORWAY SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 495 NORWAY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 496 NORWAY ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 497 NORWAY OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 498 NORWAY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 499 NORWAY ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 500 NORWAY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 501 NORWAY JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 502 NORWAY ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 503 NORWAY HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 504 NORWAY GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 505 NORWAY ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 506 NORWAY SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 507 NORWAY AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 508 NORWAY GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 509 NORWAY SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 510 NORWAY ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 511 NORWAY ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 512 NORWAY NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 513 NORWAY SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 514 NORWAY PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 515 NORWAY ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 516 NORWAY ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 517 NORWAY ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 518 NORWAY PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 519 NORWAY ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 520 NORWAY ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 521 IRELAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 522 IRELAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 523 IRELAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 524 IRELAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 525 IRELAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 526 IRELAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 527 IRELAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 528 IRELAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 529 IRELAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 530 IRELAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 531 IRELAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 532 IRELAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 533 IRELAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 534 IRELAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 535 IRELAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 536 IRELAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 537 IRELAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 538 IRELAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 539 IRELAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 540 IRELAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 541 IRELAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 542 IRELAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 543 IRELAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 544 IRELAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 545 IRELAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 546 IRELAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 547 IRELAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 548 IRELAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 549 IRELAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 550 IRELAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 551 IRELAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 552 IRELAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 553 IRELAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 554 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 555 LITHUANIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 556 LITHUANIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 557 LITHUANIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 558 LITHUANIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 559 LITHUANIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 560 LITHUANIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 561 LITHUANIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 562 LITHUANIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 563 LITHUANIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 564 LITHUANIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 565 LITHUANIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 566 LITHUANIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 567 LITHUANIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 568 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 569 LITHUANIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 570 LITHUANIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 571 LITHUANIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 572 LITHUANIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 573 LITHUANIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 574 LITHUANIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 575 LITHUANIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 576 LITHUANIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 577 LITHUANIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 578 LITHUANIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 579 LITHUANIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 580 LITHUANIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 581 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 582 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 583 LITHUANIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 584 LITHUANIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 585 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 586 LITHUANIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 587 REST OF EUROPE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

图片列表

FIGURE 1 EUROPE ADENOMYOSIS DRUGS MARKET: SEGMENTATION

FIGURE 2 EUROPE ADENOMYOSIS DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE ADENOMYOSIS DRUGS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE ADENOMYOSIS DRUGS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE ADENOMYOSIS DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE ADENOMYOSIS DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE ADENOMYOSIS DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE ADENOMYOSIS DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE ADENOMYOSIS DRUGS MARKET: END USER COVERAGE GRID

FIGURE 10 EUROPE ADENOMYOSIS DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE ADENOMYOSIS DRUGS MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN EUROPE ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 HIGH PREVALENCE OF ADENOMYOSIS DISORDER AND INCREASE THE RESEARCH AND DEVELOPMENT OF ADENOMYOSIS DRUG ARE DRIVING THE EUROPE ADENOMYOSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DIFFUSE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ADENOMYOSIS DRUGS MARKET IN 2022 & 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ADENOMYOSIS DRUGS MARKET

FIGURE 16 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, 2021

FIGURE 17 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, 2022-2029 (USD THOUSAND)

FIGURE 18 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 EUROPE ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2021

FIGURE 21 EUROPE ADENOMYOSIS DRUGS MARKET: BY TREATMENT, 2022-2029 (USD THOUSAND)

FIGURE 22 EUROPE ADENOMYOSIS DRUGS: BY TREATMENT, CAGR (2022-2029)

FIGURE 23 EUROPE ADENOMYOSIS DRUGS: BY TREATMENT, LIFELINE CURVE

FIGURE 24 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2021

FIGURE 25 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)

FIGURE 26 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 27 EUROPE ADENOMYOSIS DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 28 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2021

FIGURE 29 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)

FIGURE 30 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 31 EUROPE ADENOMYOSIS DRUGS MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 32 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, 2021

FIGURE 33 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, 2022-2029 (USD THOUSAND)

FIGURE 34 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 35 EUROPE ADENOMYOSIS DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 36 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 37 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)

FIGURE 38 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 39 EUROPE ADENOMYOSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 EUROPE ADENOMYOSIS DRUGS MARKET : SNAPSHOT (2021)

FIGURE 41 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021)

FIGURE 42 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 43 EUROPE ADENOMYOSIS DRUGS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 44 EUROPE ADENOMYOSIS DRUGS MARKET: BY TYPE (2022-2029)

FIGURE 45 EUROPE ADENOMYOSIS DRUGS MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Europe Adenomyosis Drugs Market will grow at a CAGR of 5.6% during the forecast by 2029.
The significant factors flourishing the growth of the Europe Adenomyosis Drugs Market are the High prevalence of adenomyosis disorders, and Advancement in the diagnosis of adenomyosis.
The major players operating in the Europe Adenomyosis Drugs Market are Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others..
The major countries covered in the Europe Adenomyosis Drugs Market are Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe.